The value of using polymorphisms in anti-platelet therapy
Habib Haybar, Zeinab Deris Zayeri
The value of using polymorphisms in anti-platelet therapy
OBJECTIVES and BACKGROUNDS: Cardiovascular events occure as a result of various risk factors, such as uric acid (UA), inflammation, hormones and other materials that induce C- reactive protein (CRP) expression. These factors lead to complement activation, and endothelial damages. Damaged endothelial cells release heparan sulfate which inhibits tissue factor activity and von Willed brand factor (VWVF) and causes aggregation. Finally this cascade of events cause platelets aggregation and leads to heart ischemia and cardiovascular events.
DISCUSSION:Anti-platelet therapy is an interesting premise. Anti-platelet resistance patients and bleeding as a result of using ticagrelor and prasugrel should be considered in this treatment methods. Anti-platelet drugs such as clopidogrel are prescribed in cardiovascular events. Platelets have VWF receptors and P2Y12 receptors on their surface, and thus, targeting these receptors can be useful in treatment. The active metabolites of clopidogrel bind to P2Y12R and inhibit ADP binding; thus, clopidogrel inhibits aggregation by interfering in several events as a result of the inhibition of ADP attachment to P2Y12R of the platelet. However, the polymorphisms of P2Y12 and other genes mentioned in Table 1 showed treatment resistance in anti-platelet therapy, highlighting that these SNPs can be helpful in anti-platelet therapy.
CONCLUSION: The knowledge of these SNPs may decrease the number of unwanted effects that endanger patients with cardiovascular diseases and avoids ineffective anti-platelet therapy in several patients. Clopidogrel, ticagrelor, prasugrel, and aspirin and CYP2C19 and their SNPs are very important subjects in anti-platelet therapy. To present the importance of using pharmacogenetics in anti-platelet therapy, we discuss here the association between these drugs and the SNPs for therapeutic resistance.
cardiovascular events / clopidogrel / CYP2C19 polymorphisms / anti-platelet drugs
[1] |
Amarenco P, Albers G W, Denison H, Easton J D , Evans S R , Held P, Hill M D, Jonasson J, Kasner S E , Ladenvall P , Minematsu K , Molina C A , Wang Y, Wong K S L, Johnston S C, and the SOCRATES Steering Committee and Investigators (2017). Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol, 16(4): 301–310
CrossRef
Pubmed
Google scholar
|
[2] |
Andersson H M , Siegerink B , Luken B M , Crawley J T , Algra A , Lane D A , Rosendaal F R (2012). High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood, 119(6): 1555–1560
CrossRef
Pubmed
Google scholar
|
[3] |
Andreadou I, Iliodromitis E K, Lazou A, Görbe A , Giricz Z , Schulz R , Ferdinandy P (2017). Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. Br J Pharmacol, 174(12): 1555–1569
CrossRef
Pubmed
Google scholar
|
[4] |
Angiolillo D J , Suryadevara S , Capranzano P , Bass T A (2008). Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development. Expert Opin Pharmacother, 9(16): 2893–2900160;
CrossRef
Pubmed
Google scholar
|
[5] |
Armstrong P C , Hoefer T , Knowles R B , Tucker A T , Hayman M A , Ferreira P M , Chan M V , Warner T D (2017). Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies. Arterioscler Thromb Vasc Biol, 37(5): 949–956160;
CrossRef
Pubmed
Google scholar
|
[6] |
Bonaca M P, Wiviott S D (2016). Prasugrel Versus Ticagrelor. Circulation, 134(21): 1613–1616
|
[7] |
Bozzi L M, Mitchell B D, Lewis J P, Ryan K A, Herzog W R, O’Connell J R, Horenstein R B, Shuldiner A R, Yerges-Armstrong L M (2016). The pharmacogenomics of Anti-Platelet Intervention (PAPI) Study: variation in platelet response to clopidogrel and aspirin. Curr Vasc Pharmacol, 14(1): 116–124160;
CrossRef
Pubmed
Google scholar
|
[8] |
Bro-Jeppesen J, Johansson P I, Hassager C, Wanscher M , Ostrowski S R , Bjerre M , Kjaergaard J (2016). Endothelial activation/injury and associations with severity of post-cardiac arrest syndrome and mortality after out-of-hospital cardiac arrest. Resuscitation, 107: 71–79
CrossRef
Pubmed
Google scholar
|
[9] |
Capodanno D, Dharmashankar K, Angiolillo D J (2010). Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev Cardiovasc Ther, 8(2): 151–158
CrossRef
Pubmed
Google scholar
|
[10] |
Castellano G, Melchiorre R, Loverre A , Ditonno P , Montinaro V , Rossini M , Divella C , Battaglia M , Lucarelli G , Annunziata G , Palazzo S , Selvaggi F P , Staffieri F , Crovace A , Daha M R , Mannesse M , van Wetering S , Paolo Schena F Grandaliano G, (2010). Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am J Pathol, 176(4): 1648–1659
CrossRef
Pubmed
Google scholar
|
[11] |
Cavallari L H , Obeng A O (2017). Genetic Determinants of P2Y12 Inhibitors and Clinical Implications. Interv Cardiol Clin, 6(1): 141–149
Pubmed
|
[12] |
Chan N C, Eikelboom J W, Ginsberg J S, Lauw M N, Vanassche T, Weitz J I , Hirsh J (2014). Role of phenotypic and genetic testing in managing clopidogrel therapy. Blood, 124(5): 689–699 160;
CrossRef
Pubmed
Google scholar
|
[13] |
Cohen M V, Downey J M (2014). Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered. J Cardiovasc Pharmacol Ther, 19(2): 179–190160;
CrossRef
Pubmed
Google scholar
|
[14] |
Cui H, Lin S, Chen X , Gao W, Li X, Zhou H , Du W, Wang S, Zhao R (2015). Correlation between SNPs in candidate genes and VerifyNow-detected platelet responsiveness to aspirin and clopidogrel treatment. Cardiovasc Drugs Ther, 29(2): 137–146
CrossRef
Pubmed
Google scholar
|
[15] |
Daly P L, Becker R C (2014). Pharmacogenetics of antiplatelet therapy. Curr Atheroscler Rep, 16(5): 411
CrossRef
Pubmed
Google scholar
|
[16] |
Donato R, Cannon B R, Sorci G, Riuzzi F , Hsu K, Weber D J, Geczy C L (2013). Functions of S100 proteins. Curr Mol Med, 13(1): 24–57160;
CrossRef
Pubmed
Google scholar
|
[17] |
Farthing D E, Farthing C A, Xi L (2015). Inosine and hypoxanthine as novel biomarkers for cardiac ischemia: from bench to point-of-care. Exp Biol Med (Maywood), 240(6): 821–831160;
CrossRef
Pubmed
Google scholar
|
[18] |
Fontana P, Cattaneo M, Combescure C , Reny J L (2013). Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping. J Am Heart Assoc, 2(2): e000131
CrossRef
Pubmed
Google scholar
|
[19] |
Friede K, Li J, Voora D (2017). Use of pharmacogenetic information in the treatment of cardiovascular disease. Clin Chem, 63(1): 177–185160;
CrossRef
Pubmed
Google scholar
|
[20] |
Gajda S N, Kołtowski Ł, Tomaniak M (2014). Most recent evidence behind aggregometry and genotyping methods as platelet function testing for tailored anti-platelet treatment among PCI patients. Adv Clin Exp Med, 24(4): 687–693
|
[21] |
Golukhova E Z , Ryabinina M N , Bulaeva N I , Grigorian M V , Kubova M Ch , Serebruany V L (2015). Clopidogrel response variability: impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting. Am J Ther, 22(3): 222–230
CrossRef
Pubmed
Google scholar
|
[22] |
Gorsuch W B, Chrysanthou E, Schwaeble W J , Stahl G L (2012). The complement system in ischemia-reperfusion injuries. Immunobiology, 217(11): 1026–1033160;
CrossRef
Pubmed
Google scholar
|
[23] |
Hasan M S, Basri H B, Hin L P, Stanslas J (2013). Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. Int J Neurosci, 123(3): 143–154160;
CrossRef
Pubmed
Google scholar
|
[24] |
Hurst N L, Nooney V B, Raman B, Chirkov Y Y , De Caterina R , Horowitz J D (2013). Clopidogrel “resistance”: pre- vs post-receptor determinants. Vascul Pharmacol, 59(5-6): 152–161160;
CrossRef
Pubmed
Google scholar
|
[25] |
Jahn K, Suchodolski K, Schäfer A , Sahlmann B , Küster U , Echtermeyer F , Calmer S , Theilmeier G , Johanning K (2017). Effect of Clopidogrel on Thrombus Formation in an Ex Vivo Parallel Plate Flow Chamber Model Cannot Be Reversed by Addition of Platelet Concentrates or vWF Concentrate. Anesth Analg, 124(4): 1091–1098160;
CrossRef
Pubmed
Google scholar
|
[26] |
Jian L, Lu Y, Lu S , Lu C (2016). Chemical Chaperone 4-Phenylbutyric Acid Reduces Cardiac Ischemia/Reperfusion Injury by Alleviating Endoplasmic Reticulum Stress and Oxidative Stress. Med Sci Monit, 22: 5218–5227
CrossRef
Pubmed
Google scholar
|
[27] |
Jiménez-Brítez G , Freixa X , Flores-Umanzor E , San Antonio R , Caixal G , Garcia J , Hernandez-Enriquez M , Andrea R , Regueiro A , Masotti M , Brugaletta S , Martin V , Sabaté M (2017). Out-of-hospital cardiac arrest and stent thrombosis: Ticagrelor versus clopidogrel in patients with primary percutaneous coronary intervention under mild therapeutic hypothermia. Resuscitation, 114: 141–145
CrossRef
Pubmed
Google scholar
|
[28] |
Kaikita K, Ono T, Iwashita S , Nakayama N , Sato K, Horio E, Nakamura S , Tsujita K , Tayama S , Hokimoto S , Sakamoto T , Nakao K , Oshima S , Sugiyama S , Ogawa H (2014). Impact of CYP2C19 polymorphism on platelet function tests and coagulation and inflammatory biomarkers in patients undergoing percutaneous coronary intervention. J Atheroscler Thromb, 21(1): 64–76160;
CrossRef
Pubmed
Google scholar
|
[29] |
Kosacka M, Brzecka A, Piesiak P , Korzeniewska A , Jankowska R (2015). Soluble ligand CD40 and uric acid as markers of atheromatosis in patients with obstructive sleep apnea. Adv Exp Med Biol, 839: 55–60
CrossRef
Pubmed
Google scholar
|
[30] |
Kubo T, Ino Y, Matsuo Y , Shiono Y , Kameyama T , Yamano T , Katayama Y , Taruya A , Nishiguchi T , Satogami K , Kashiyama K , Orii M, Kuroi A, Yamaguchi T , Tanaka A , Hozumi T , Akasaka T (2017). Reduction of in-stent thrombus immediately after percutaneous coronary intervention by pretreatment with prasugrel compared with clopidogrel: An optical coherence tomography study. J Cardiol, 69(2): 436–441160;
CrossRef
Pubmed
Google scholar
|
[31] |
Lippi G, Franchini M, Cervellin G (2013). Diagnosis and management of ischemic heart disease. Semin Thromb Hemost, 39(2): 202–213
CrossRef
Pubmed
Google scholar
|
[32] |
Lowe G, Rumley A (2014). The relevance of coagulation in cardiovascular disease: what do the biomarkers tell us? Thromb Haemost, 112(5): 860–867160;
CrossRef
Pubmed
Google scholar
|
[33] |
Majumdar S, Rustagi S, Mondal S , Rijhwani V , Kaur J, Sharma P (2014). Aspirin resistance: An emerging clinical predicament is associated with single nucleotide polymorphisms. Int J Basic Appl Biol, 2(2): 63–68
|
[34] |
Malhotra N, Abunassar J, Wells G A , McPherson R , Fu A, Hibbert B, Labinaz M , Le May M , Dick A, Glover C, Froeschl M , Marquis J F , Tran L, Bernick J, Chong A Y , So D Y , and the CArdiovascular Percutaneous Intervention TriAL (CAPITAL) investigators (2015). A pharmacodynamic comparison of a personalized strategy for anti-platelet therapy versus ticagrelor in achieving a therapeutic window. Int J Cardiol, 197: 318–325
CrossRef
Pubmed
Google scholar
|
[35] |
Martínez-Quintana E , Tugores A (2015). Clopidogrel: A multifaceted affair. J Clin Pharmacol, 55(1): 1–9
CrossRef
Pubmed
Google scholar
|
[36] |
Men J L, Ren J, Ma R , Wang Z X (2015). High Level of von Willebrand Factor in Non-ST Segment Elevation Myocardial Infarction Patients Predicted Cardiovascular Ischemic Events After Off-Pump Coronary Artery Bypass Surgery. Int Heart J, 56(3): 298–302 160;
CrossRef
Pubmed
Google scholar
|
[37] |
Nadir Y (2014). Heparanase and coagulation-new insights. Rambam Maimonides Med J, 5(4): e0031160;
CrossRef
Pubmed
Google scholar
|
[38] |
Nie X Y, Li J L, Zhang Y, Xu Y , Yang X L , Fu Y, Liang G K, Lu Y, Liu J , Shi L W (2017). Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity. J Zhejiang Univ Sci B, 18(1): 37–47
CrossRef
Pubmed
Google scholar
|
[39] |
Olechowski B, Ashby A, Mariathas M , Khanna V , Mahmoudi M , Curzen N (2017). Is arachidonic acid stimulation really a test for the response to aspirin? Time to think again? Expert Rev Cardiovasc Ther, 15(1): 35–46
CrossRef
Pubmed
Google scholar
|
[40] |
Ou W, He Y, Li A , Liu B, Jin L (2016). Genotype Frequencies of CYP2C19, P2Y12 and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness. Int Heart J, 57(5): 586–592
CrossRef
Pubmed
Google scholar
|
[41] |
Perry C G, Shuldiner A R (2013). Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? J Hum Genet, 58(6): 339–345
CrossRef
Pubmed
Google scholar
|
[42] |
Qiu L N, Sun Y, Wang L , Han R F , Xia X S , Liu J, Li X (2015). Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel. Eur J Pharmacol, 747: 29–35
CrossRef
Pubmed
Google scholar
|
[43] |
Rao H,
|
[44] |
Ray S (2014). Clopidogrel resistance: the way forward. Indian Heart J, 66(5): 530–534
CrossRef
Pubmed
Google scholar
|
[45] |
Razzaghi H, Tempczyk-Russell A, Haubold K , Santorico S A , Shokati T , Christians U , Churchill M E (2013). Genetic and structure-function studies of missense mutations in human endothelial lipase. PLoS One, 8(3): e55716
CrossRef
Pubmed
Google scholar
|
[46] |
Rollini F, Franchi F, Angiolillo D J (2017). Drug-drug interactions when switching between intravenous and Oral P2Y 12 receptor inhibitors. JACC Cardiovasc Interv, 10(2): 130–132
|
[47] |
Scott S A, Sangkuhl K, Gardner E E , Stein C M , Hulot J S , Johnson J A , Roden D M , Klein T E , Shuldiner A R , and the Clinical Pharmacogenetics Implementation Consortium (2011). Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther, 90(2): 328–332160;
CrossRef
Pubmed
Google scholar
|
[48] |
Sen H M, Silan F, Silan C , Degirmenci Y , Ozisik Kamaran H I (2015). Effects of CYP2C19 and P2Y12 gene polymorphisms on clinical results of patients using clopidogrel after acute Ischemic cerebrovascular disease. Balkan J Med Genet, 17(2): 37–41
Pubmed
|
[49] |
Sharma M Mascarenhas D A (2017). Ticagrelor associated heart block: The need for close and continued monitoring. Case Rep Cardiol, 2017; 5074891
|
[50] |
Sheikh Rezaei S , Geroldinger A , Heinze G , Reichardt B , Wolzt M (2017). Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. Int J Cardiol, 235: 61–66
CrossRef
Pubmed
Google scholar
|
[51] |
Shuldiner A R ,
|
[52] |
Spiel A O, Gilbert J C, Jilma B (2008). von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation, 117(11): 1449–1459
CrossRef
Pubmed
Google scholar
|
[53] |
Stone G W, Witzenbichler B, Weisz G , Rinaldi M J , Neumann F J , Metzger D C , Henry T D , Cox D A , Duffy P L , Mazzaferri E , Gurbel P A , Xu K, Parise H, Kirtane A J , Brodie B R , Mehran R , Stuckey T D , and the ADAPT-DES Investigators (2013). Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet, 382(9892): 614–623160;
CrossRef
Pubmed
Google scholar
|
[54] |
Sumaya W, Storey R F (2017). Ticagrelor: Effects Beyond the P2Y12 Receptor. Interv Cardiol Clin, 6(1): 49–55
Pubmed
|
[55] |
Tekin G, Tekin Y K, Erbay A R, Turhan H, Yetkin E (2013). Serum uric acid levels are associated with atrial fibrillation in patients with ischemic heart failure. Angiology, 64(4): 300–303160;
CrossRef
Pubmed
Google scholar
|
[56] |
Thomas M R, Lip G Y (2017). Novel Risk Markers and Risk Assessments for Cardiovascular Disease. Circ Res, 120(1): 133–149
CrossRef
Pubmed
Google scholar
|
[57] |
Thomas M R, Storey R F (2014). Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes. J Cardiovasc Transl Res, 7(1): 19–28160;
CrossRef
Pubmed
Google scholar
|
[58] |
Tough D F, Tak P P, Tarakhovsky A, Prinjha R K (2016). Epigenetic drug discovery: breaking through the immune barrier. Nat Rev Drug Discov, 15(12): 835–853160;
CrossRef
Pubmed
Google scholar
|
[59] |
Ulehlova J, Slavik L, Kucerova J , Krcova V , Vaclavik J , Indrak K (2014). Genetic polymorphisms of platelet receptors in patients with acute myocardial infarction and resistance to antiplatelet therapy. Genet Test Mol Biomarkers, 18(9): 599–604160;
CrossRef
Pubmed
Google scholar
|
[60] |
Verlinden N J , Coons J C , Iasella C J , Kane-Gill S L (2017). Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention. J Cardiovasc Pharmacol Ther, doi: 10.117711074248417698042
Pubmed
|
[61] |
Wang K, Yuan Y, Liu X , Lau W B , Zuo L, Wang X, Ma L , Jiao K, Shang J, Wang W , Ma X, Liu H (2016). Cardiac Specific Overexpression of Mitochondrial Omi/HtrA2 Induces Myocardial Apoptosis and Cardiac Dysfunction. Sci Rep, 6(1): 37927160;
CrossRef
Pubmed
Google scholar
|
[62] |
Xin Y G, Zhang H S, Li Y Z, Guan Q G, Guo L, Gao Y , Yu H J , Zhang X G , Xu F, Zhang Y L, Jia D L, Sun Y X, Qi G X, Tian W (2017). Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome. Int J Cardiol, 228: 275–279
CrossRef
Pubmed
Google scholar
|
[63] |
Yang H H, Chen Y, Gao C Y (2016). Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel. Cardiovasc Ther, 34(6): 460–467160;
CrossRef
Pubmed
Google scholar
|
[64] |
Yi X, Lin J, Wang Y , Zhou Q, Wang C, Cheng W , Chi L (2016). Association of cytochrome P450 genetic variants with clopidogrel resistance and outcomes in acute ischemic stroke. J Atheroscler Thromb, 23(10): 1188–1200160;
CrossRef
Pubmed
Google scholar
|
[65] |
Yi X, Zhou Q, Wang C , Lin J, Liu P, Fu C (2017). Platelet receptor Gene (P2Y12, P2Y1) and platelet glycoprotein Gene (GPIIIa) polymorphisms are associated with antiplatelet drug responsiveness and clinical outcomes after acute minor ischemic stroke. Eur J Clin Pharmacol, 73(4): 437–443160;
CrossRef
Pubmed
Google scholar
|
[66] |
Yip V L M , Pirmohamed M (2013). Expanding role of pharmacogenomics in the management of cardiovascular disorders. Am J Cardiovasc Drugs, 13(3): 151–162
CrossRef
Pubmed
Google scholar
|
/
〈 | 〉 |